Advertisement

Classification, causes, and epidemiology

Chapter
  • 2.2k Downloads

Abstract

The depressive disorders comprise a heterogeneous group of illnesses that are characterized by differing degrees of sad mood and associated cognitive, neurovegetative, and psychomotor alterations. Depression is currently the fourth most disabling medical condition in the world and it is predicted to be second only to ischemic heart disease with regard to disability by 2020 [1,2].

Keywords

Depressive Symptom Major Depressive Disorder Suicidal Ideation Depressive Episode Postpartum Depression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: global burden of disease study. Lancet 1997; 349:1498–1504.PubMedCrossRefGoogle Scholar
  2. 2.
    Lopez AD, Mathers CD. Measuring the global burden of disease and epidemiological transitions: 2002–2030. Ann Tropical Med Parasitol 2006; 100:481–499.CrossRefGoogle Scholar
  3. 3.
    Remick RA, Sadovnick AD, Lam RW, et al. Major depression, minor depression, and double-depression: are they distinct clinical entities? Am J Med Genet 1996; 67:347–353.PubMedCrossRefGoogle Scholar
  4. 4.
    American Psychiatric Association. The Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington DC: APA, 1994.Google Scholar
  5. 5.
    World Health Organization. International Classification of Mental and Behavioral Disorders, 10th revision (ICD-10). Geneva: WHO, 1992.Google Scholar
  6. 6.
    Bostwick JM, Pankratz VS. Affective disorder and suicide risk: a reexamination. Am J Psychiatry 2000; 157:1924–1932.CrossRefGoogle Scholar
  7. 7.
    Kandel ER. A new intellectual framework for psychiatry. Am J Psychiatry 1998; 55:457–469.Google Scholar
  8. 8.
    Caspi A, Sudgen K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301:386–389.PubMedCrossRefGoogle Scholar
  9. 9.
    Richelson E. The clinical relevance of antidepressant interaction with neurotransmitter transporters and receptors. Psychopharmacol Bull 2002; 36:133–150.PubMedGoogle Scholar
  10. 10.
    Brown WG, Craig TKJ, Harris TO. Parental maltreatment and proximal risk factors using the Childhood Experience of Care and Abuse (CECA) instrument: a life course study of adult chronic depression – 5. J Affect Disord 2008; 110:222–233.PubMedCrossRefGoogle Scholar
  11. 11.
    Waraich P, Goldner EM, Somers JM,et al. Prevalence and incidence studies of mood disorders: a systematic review of the literature. Can J Psychiatry 2004; 49:124–138.PubMedGoogle Scholar
  12. 12.
    Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289:3095–3105.PubMedCrossRefGoogle Scholar
  13. 13.
    Rush AJ. STAR*D: What have we learned? Am J Psychiatry 2007; 164:201–204.PubMedCrossRefGoogle Scholar
  14. 14.
    Mueller TI, Leon AC. Recovery, chronicity, and levels of psychopathology in major depressive disorder. Psychiatr Clin North Am 1996; 19:85–102.PubMedCrossRefGoogle Scholar
  15. 15.
    Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996; 19:179–200.PubMedCrossRefGoogle Scholar
  16. 16.
    Judd LL, Akiskal HS, Maser JD, et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 1998; 55:694–700.PubMedCrossRefGoogle Scholar
  17. 17.
    AHCPR Depression Guideline Panel. Clinical Practice Guideline. Number 5. Depression in Primary Care, vol 1. Detection and Diagnosis. Rockville, MD: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1993.Google Scholar
  18. 18.
    Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8–19.PubMedCrossRefGoogle Scholar
  19. 19.
    Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000; 342:1462–1470.PubMedCrossRefGoogle Scholar
  20. 20.
    Nemeroff CB, Heim CM, Thase ME, et al. Differential responses to psychotherapy versus pharmacotherapy in the treatment of patients with chronic forms of depression. Proc Natl Acad Sci USA 2003; 100:14293–14296.PubMedCrossRefGoogle Scholar
  21. 21.
    Schatzberg AF, Rush AJ, Arnow BA, et al. Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. Arch Gen Psychiatry 2005; 62:513–520.PubMedCrossRefGoogle Scholar
  22. 22.
    O’Hara MW, Swain AM. Rates and risk of postpartum depression: a meta analysis. Int Rev Psychiatry 1996; 8:37–54.CrossRefGoogle Scholar

Copyright information

© Springer London 2011

Authors and Affiliations

  1. 1.PittsburghUSA

Personalised recommendations